MNC semi-annual report: Novartis, Johnson & Johnson, Abbott, Roche "lead the way"!

Recently, major multinational pharmaceutical companies have announced their results for the first half of 202 Profits of Novartis and Johnson & Johnson declined; Bojian’s net profit doubled in the second quarter, but the stock market fell; Abbott’s profit increased, but was still negatively affected by the recall and discontinuation of infant formula in February; Roche’s innovative drug performance far exceeded expectations, making up for the disadvantage of “old drug.

From each performance report, you can see the business status and performance of the company for a certain period of time, and also can spy on the strategic adjustment of the compa.

This reflects the fact that multinational pharmaceutical companies have returned to their core businesses in recent years, instead of pursuing diversification blindly, and focusing on the main business is becoming more and more obvio.

On July 19, Novartis announced its results for the first half of 202 The announcement showed that Novartis’ net sales revenue in the first half of the year reached US$2312 billion, which was basically the same as the previous year; the net profit attributable to ordinary shareholders of the parent company was US$916 billion, a year-on-year decrease of 29

In terms of innovative drugs, Novartis' innovative drug net sales in the first half of 2022 were US$26 billion (0%, +5% c.

Notably, emerging growth markets grew +4% (+10% cc), with China contributing $6 billion in revenue, up 11% year-over-year, mainly driven by Cosent.

2

On July 19, Johnson & Johnson released its second-quarter 2022 financial report and first-half financial da.

At present, Johnson & Johnson is mainly engaged in three major businesses: medical equipment, pharmaceuticals and consumer goo.

The announcement shows that the strong growth of the pharmaceutical business mainly comes from several products such as daratumumab (Darzalex), ustekinumab (Stelara), apalutamide (Erleada) and guselkumab (Tremfya) product promoti.

3

On July 20, local time, Biogen announced its financial results for the second quarter of 202 In the first half of 2022, total revenue was US$121 billion, down 4% year-on-year; net profit was US$277 billion, down 17% year -on-ye.

Surprisingly, although the second-quarter earnings beat expectations, the market still responded with a slu.

However, the lack of the latest information about Aduhelm in this financial report led the market to be pessimistic about its future; in addition, in April Biogen announced the withdrawal of Aduhelm's listing application in Europe, and in May Biogen stated in its first quarterly report that the decision was basically Cancellation of Aduhelm's commercialization measur.

4

On July 20, Abbott announced its results for the second quarter of 2022, with revenue of $1257 billion, a year-on-year increase of 11%, and net profit of $018 billion, a year-on-year increase of 6

By business, pharmaceutical sales were $223 billion, up 7% year over ye.

Abbott said its global sales were negatively impacted by a recall and shutdown of infant formula in Februa.

5

On July 21, Roche disclosed its performance for the first half of 202 According to the financial report, in the first half of the year, Roche’s total revenue was 3295 billion Swiss francs (about 3332 billion US dollars), and its net profit was 161 billion Swiss francs, a year-on-year increase of 12%; R&D investment was 628 billion Swiss francs, basically the same as the same period last ye.

Among them, the revenue of the pharmaceutical sector was 2347 billion Swiss francs, a year-on-year increase of 3%, accounting for 69%, of which China was 618 billion Swiss francs; the other accounted for the diagnostic busine.

Specifically, Roche's first batch of Hemlibra and Ocrevus in 2017 increased by 30% and 17% respectively; the first batch of Polivy in 2019 Growth of 91%; the first batch of risprom (Evrysdi) in 2020 increased by 106%, Phesgo increased by 241%, and satrilizumab (Enspryng) increased by 13

The outstanding performance of innovative drugs has greatly compensated for the 21% decline in sales of rituximab (MabThera), bevacizumab (Avastin) and trastuzumab (Herceptin) due to the impact of biosimilar drugs, respective.

29% and 16% disadvanta.

On the same day, Roche also announced the appointment of new executiv.

The board of directors has appointed Thomas Schinecker, head of Roche’s diagnostics division, as Roche’s new CEO, effective March 15, 2023; it is planned to nominate former CEO Severin Schwan at the annual general meeti.

New Chairman of the Boa.

1

In April, Novartis announced it would adopt a new organizational structure and operating mod.

The Pharma and Oncology business units will be integrated and two separate commercial organizations with stronger geographic focus will be created—the.


Innovative Medicines Division and the International Innovative Medicines Divisi.

Both divisions will have full P&L responsibility across all therapeutic areas and will have ownership of customer experience, marketing and sales, and market access in their respective marke.

The establishment of an independent.


business organization enhances Novartis' ability to achieve its goal of becoming a top-five company by sales in the United States, while maintaining and growing its international leadersh.

The new model will also help Novartis to sharpen its focus and commitment to the company's core therapeutic areas of cardiovascular, hematology, solid tumors, immunology and neuroscien.

In this semi-annual report, it is pointed out that with the restructuring and integration, Novartis expects to save about 5 billion US dollars in sales expenses by 202 The savings will be used to invest in follow-on pipelines and contribute to mid- to long-term profit growth in its Innovative Medicines segment (I.

Recently, Sandoz, Novartis’ generic drug business unit, said to the public that Novartis will decide to divest or sell Sandoz by the end of this ye.

The semi-annual report shows that Novartis' strategic review of Sandoz is in progress, and it is expected to provide an update by the end of 2022 at the late.

2

In November 2021, Johnson & Johnson announced its latest spin-off plan, splitting the company into two public companies, one focused on pharmaceuticals and medical devices and the other focused on consumer products, planned to split over the next 18 to 24 months Consumer segment, costs $500 million to $1 billi.

The Johnson & Johnson Pharmaceuticals and Medical Devices division will retain the Johnson & Johnson na.

According to such a spin-off plan and revenue data in 2021, the "New Johnson & Johnson" consisting of pharmaceutical and medical device businesses will have a revenue of US$71 billion in 2021, with pharmaceutical business accounting for 66% and medical device business accounting for 3
Consumer health business accounted for 1

In the first half of 2022, both the pharmaceutical and medical device businesses grew, and the consumer health business underperformed, down 4% year-on-ye.

From an industry perspective, this underscores the pressure on large, diversified companies to simplify their structures to improve focus, especially in healthcare, where the slow-and-steady business of selling consumer products such as shampoos and moisturizers has been linked to the development and marketing of dru.

High-risk, high-reward jobs are increasingly differe.

3

In February 2022, Roche China's two product lines of anti-infection and osteoporosis have completed the merg.

Roche China said that this restructuring does not involve staff layof.

The person in charge of the original anti-infective disease area is now in charge of its strategy and product excellence marketing team, and the person in charge of the original osteoporosis field will continue to lead the new osteoporosis treatment and anti-infective treatment field tea.

From the product point of view, these two product lines do not account for a large proportion of Roche's reven.

Roche's pharmaceutical business mainly focuses on the fields of oncology, immunity, neurology, hemophilia, infectious diseases, ophthalmology and other diseas.

In recent years, Roche has started to iteratively upgrade the "agile transformation" mod.

From the original "product line business model", the "regional model" of Guangdong and Sichuan and Chongqing, and the "ecosystem model" of lymphoma, into a unified "customer interaction business model" to create a business centered on the field of disease treatment fo.

In 2021, the "ecosphere model" will be officially launched, and the three models will be unified and integrated into a "customer interaction business model" centered on the field of oncology and specialty medici.

4

While most of them gather their main businesses and divest some businesses and products, there are also some companies who are selling products frequently to speed up their "slimmi.

"

Recently, Sanofi and Neuraxpharm reached an agreement to sell 17 drugs to Neuraxpharm for an undisclosed amou.

The drugs are understood to include two product portfolios for central nervous system (CNS) disorders, pain and vascular disorde.

The 17 Sanofi drugs collectively make up 38 brands, and together this suite of products is sold in more than 50 countries around the wor.

Since the beginning of this year, Sanofi has still made frequent moves in terms of "slim dow.

In April, Sanofi announced that the French securities market regulator AMF has approved the listing prospectus of its API company EUROA.

Once approved by the general meeting of shareholders, it is expected to be spun off and listed on Euronext Paris on May
In June, Sanofi sold its longtime partner Regeneron's exclusive global rights to the cancer drug Libtayo for $900 milli.

Editor: Liu Xiaomei